SINGLE-DRUG PARENTERAL ESTROGEN-TREATMENT IN PROSTATIC-CANCER - A STUDY OF 2 MAINTENANCE-DOSE REGIMENS

被引：23

作者：

STEGE, R ^{[1
]}

CARLSTROM, K

COLLSTE, L

ERIKSSON, A

HENRIKSSON, P

POUSETTE, A

VONSCHOULTZ, B

机构：

[1] KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT UROL,S-14186 HUDDINGE,SWEDEN

[2] KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT INTERNAL MED,S-14186 HUDDINGE,SWEDEN

[3] KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN

[4] UMEA UNIV HOSP,DEPT OBSTET & GYNECOL,S-90185 UMEA,SWEDEN

来源：

PROSTATE | 1989年 / 14卷 / 02期

关键词：

D O I：

10.1002/pros.2990140211

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：183 / 188

页数：6

共 15 条

[1]

Blackard C E, 1973, Urology, V1, P553, DOI 10.1016/0090-4295(73)90515-3

[2] INFLUENCE OF ORCHIDECTOMY OR ESTROGEN-TREATMENT ON SERUM LEVELS OF PREGNANCY ASSOCIATED ALPHA-2-GLYCOPROTEIN AND SEX-HORMONE BINDING GLOBULIN IN PATIENTS WITH PROSTATIC-CANCER [J].

CARLSTROM, K ;

ERIKSSON, A ;

GUSTAFSSON, SA ;

HENRIKSSON, P ;

POUSETTE, A ;

STEGE, R ;

VONSCHOULTZ, B .

INTERNATIONAL JOURNAL OF ANDROLOGY, 1985, 8 (01) :21-27

[3]

DAEHLIN L, 1985, THESIS UMEA U

[4]

DAMBER JE, 1987, PROSTATE CANCER A, P513

[5] CORRELATION OF PRETREATMENT PLASMA-LEVELS OF ESTRADIOL AND SEX-HORMONE-BINDING GLOBULIN-BINDING CAPACITY WITH CLINICAL STAGE AND SURVIVAL OF PATIENTS WITH PROSTATIC-CANCER [J].

HAAPIAINEN, R ;

RANNIKKO, S ;

ADLERCREUTZ, H ;

ALFTHAN, O .

PROSTATE, 1986, 8 (02) :127-137

[6] A COMPARISON OF LIVER PROTEIN INDUCTION IN POST-MENOPAUSAL WOMEN DURING ORAL AND PERCUTANEOUS ESTROGEN REPLACEMENT THERAPY [J].

HOLST, J ;

CAJANDER, S ;

CARLSTROM, K ;

DAMBER, MG ;

VONSCHOULTZ, B .

BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1983, 90 (04) :355-360

[7]

Jonsson G, 1975, Vitam Horm, V33, P351

[8] TREATMENT OF PROSTATE-CANCER WITH GONADOTROPIN-RELEASING-HORMONE AGONISTS [J].

LABRIE, F ;

DUPONT, A ;

BELANGER, A ;

STARNAUD, R ;

GIGUERE, M ;

LACOURCIERE, Y ;

EMOND, J ;

MONFETTE, G .

ENDOCRINE REVIEWS, 1986, 7 (01) :67-74

[9] FLUTAMIDE ELIMINATES THE RISK OF DISEASE FLARE IN PROSTATIC-CANCER PATIENTS TREATED WITH A LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST [J].

LABRIE, F ;

DUPONT, A ;

BELANGER, A ;

LACHANCE, R .

JOURNAL OF UROLOGY, 1987, 138 (04) :804-806

[10]

LUUKARINEN O, 1977, INVEST UROL, V17, P328

← 1 2 →